Eintrag weiter verarbeiten
Vigabatrin in epilepsy in mentally retarded patients.
Gespeichert in:
| Zeitschriftentitel: | British Journal of Clinical Pharmacology |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | British Journal of Clinical Pharmacology, 27, 1989, S1 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Matilainen, R Pitkanen, A Ruutiainen, T Mervaala, E Riekkinen, P Matilainen, R Pitkanen, A Ruutiainen, T Mervaala, E Riekkinen, P |
|---|---|
| author |
Matilainen, R Pitkanen, A Ruutiainen, T Mervaala, E Riekkinen, P |
| spellingShingle |
Matilainen, R Pitkanen, A Ruutiainen, T Mervaala, E Riekkinen, P British Journal of Clinical Pharmacology Vigabatrin in epilepsy in mentally retarded patients. Pharmacology (medical) Pharmacology |
| author_sort |
matilainen, r |
| spelling |
Matilainen, R Pitkanen, A Ruutiainen, T Mervaala, E Riekkinen, P 0306-5251 1365-2125 Wiley Pharmacology (medical) Pharmacology http://dx.doi.org/10.1111/j.1365-2125.1989.tb03471.x <jats:p>1. The anticonvulsant potency of vigabatrin (gamma‐vinyl GABA, GVG) was studied in an open trial in a group of 21 mentally handicapped patients with drug‐resistant epilepsy. 2. With this treatment one third of these patients had more than 50% reduction in seizure frequency. The anticonvulsant effect appeared during the first month of therapy and was maintained during a 7‐month study. The side effects were mild: mainly tiredness, aggressiveness, and ataxia. Other anticonvulsant drugs remained at baseline levels during GVG therapy. GVG was not found to modulate EEG recordings. 3. According to our results, GVG is effective for treating intractable epilepsy in mentally handicapped patients.</jats:p> Vigabatrin in epilepsy in mentally retarded patients. British Journal of Clinical Pharmacology |
| doi_str_mv |
10.1111/j.1365-2125.1989.tb03471.x |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjEzNjUtMjEyNS4xOTg5LnRiMDM0NzEueA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjEzNjUtMjEyNS4xOTg5LnRiMDM0NzEueA |
| institution |
DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
Wiley, 1989 |
| imprint_str_mv |
Wiley, 1989 |
| issn |
0306-5251 1365-2125 |
| issn_str_mv |
0306-5251 1365-2125 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
matilainen1989vigabatrininepilepsyinmentallyretardedpatients |
| publishDateSort |
1989 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
British Journal of Clinical Pharmacology |
| source_id |
49 |
| title |
Vigabatrin in epilepsy in mentally retarded patients. |
| title_unstemmed |
Vigabatrin in epilepsy in mentally retarded patients. |
| title_full |
Vigabatrin in epilepsy in mentally retarded patients. |
| title_fullStr |
Vigabatrin in epilepsy in mentally retarded patients. |
| title_full_unstemmed |
Vigabatrin in epilepsy in mentally retarded patients. |
| title_short |
Vigabatrin in epilepsy in mentally retarded patients. |
| title_sort |
vigabatrin in epilepsy in mentally retarded patients. |
| topic |
Pharmacology (medical) Pharmacology |
| url |
http://dx.doi.org/10.1111/j.1365-2125.1989.tb03471.x |
| publishDate |
1989 |
| physical |
|
| description |
<jats:p>1. The anticonvulsant potency of vigabatrin (gamma‐vinyl GABA, GVG) was studied in an open trial in a group of 21 mentally handicapped patients with drug‐resistant epilepsy. 2. With this treatment one third of these patients had more than 50% reduction in seizure frequency. The anticonvulsant effect appeared during the first month of therapy and was maintained during a 7‐month study. The side effects were mild: mainly tiredness, aggressiveness, and ataxia. Other anticonvulsant drugs remained at baseline levels during GVG therapy. GVG was not found to modulate EEG recordings. 3. According to our results, GVG is effective for treating intractable epilepsy in mentally handicapped patients.</jats:p> |
| container_issue |
S1 |
| container_start_page |
0 |
| container_title |
British Journal of Clinical Pharmacology |
| container_volume |
27 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792336923204780034 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:08:09.482Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Vigabatrin+in+epilepsy+in+mentally+retarded+patients.&rft.date=1989-02-01&genre=article&issn=1365-2125&volume=27&issue=S1&jtitle=British+Journal+of+Clinical+Pharmacology&atitle=Vigabatrin+in+epilepsy+in+mentally+retarded+patients.&aulast=Riekkinen&aufirst=P&rft_id=info%3Adoi%2F10.1111%2Fj.1365-2125.1989.tb03471.x&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792336923204780034 |
| author | Matilainen, R, Pitkanen, A, Ruutiainen, T, Mervaala, E, Riekkinen, P |
| author_facet | Matilainen, R, Pitkanen, A, Ruutiainen, T, Mervaala, E, Riekkinen, P, Matilainen, R, Pitkanen, A, Ruutiainen, T, Mervaala, E, Riekkinen, P |
| author_sort | matilainen, r |
| container_issue | S1 |
| container_start_page | 0 |
| container_title | British Journal of Clinical Pharmacology |
| container_volume | 27 |
| description | <jats:p>1. The anticonvulsant potency of vigabatrin (gamma‐vinyl GABA, GVG) was studied in an open trial in a group of 21 mentally handicapped patients with drug‐resistant epilepsy. 2. With this treatment one third of these patients had more than 50% reduction in seizure frequency. The anticonvulsant effect appeared during the first month of therapy and was maintained during a 7‐month study. The side effects were mild: mainly tiredness, aggressiveness, and ataxia. Other anticonvulsant drugs remained at baseline levels during GVG therapy. GVG was not found to modulate EEG recordings. 3. According to our results, GVG is effective for treating intractable epilepsy in mentally handicapped patients.</jats:p> |
| doi_str_mv | 10.1111/j.1365-2125.1989.tb03471.x |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjEzNjUtMjEyNS4xOTg5LnRiMDM0NzEueA |
| imprint | Wiley, 1989 |
| imprint_str_mv | Wiley, 1989 |
| institution | DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 0306-5251, 1365-2125 |
| issn_str_mv | 0306-5251, 1365-2125 |
| language | English |
| last_indexed | 2024-03-01T15:08:09.482Z |
| match_str | matilainen1989vigabatrininepilepsyinmentallyretardedpatients |
| mega_collection | Wiley (CrossRef) |
| physical | |
| publishDate | 1989 |
| publishDateSort | 1989 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | British Journal of Clinical Pharmacology |
| source_id | 49 |
| spelling | Matilainen, R Pitkanen, A Ruutiainen, T Mervaala, E Riekkinen, P 0306-5251 1365-2125 Wiley Pharmacology (medical) Pharmacology http://dx.doi.org/10.1111/j.1365-2125.1989.tb03471.x <jats:p>1. The anticonvulsant potency of vigabatrin (gamma‐vinyl GABA, GVG) was studied in an open trial in a group of 21 mentally handicapped patients with drug‐resistant epilepsy. 2. With this treatment one third of these patients had more than 50% reduction in seizure frequency. The anticonvulsant effect appeared during the first month of therapy and was maintained during a 7‐month study. The side effects were mild: mainly tiredness, aggressiveness, and ataxia. Other anticonvulsant drugs remained at baseline levels during GVG therapy. GVG was not found to modulate EEG recordings. 3. According to our results, GVG is effective for treating intractable epilepsy in mentally handicapped patients.</jats:p> Vigabatrin in epilepsy in mentally retarded patients. British Journal of Clinical Pharmacology |
| spellingShingle | Matilainen, R, Pitkanen, A, Ruutiainen, T, Mervaala, E, Riekkinen, P, British Journal of Clinical Pharmacology, Vigabatrin in epilepsy in mentally retarded patients., Pharmacology (medical), Pharmacology |
| title | Vigabatrin in epilepsy in mentally retarded patients. |
| title_full | Vigabatrin in epilepsy in mentally retarded patients. |
| title_fullStr | Vigabatrin in epilepsy in mentally retarded patients. |
| title_full_unstemmed | Vigabatrin in epilepsy in mentally retarded patients. |
| title_short | Vigabatrin in epilepsy in mentally retarded patients. |
| title_sort | vigabatrin in epilepsy in mentally retarded patients. |
| title_unstemmed | Vigabatrin in epilepsy in mentally retarded patients. |
| topic | Pharmacology (medical), Pharmacology |
| url | http://dx.doi.org/10.1111/j.1365-2125.1989.tb03471.x |